CIC

Across TCGA pan-cancer cohorts, CIC Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CIC data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher CIC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CIC expression acts as an unfavorable survival marker, although some lineages such as UCEC and LGG show a favorable association.

UCS, PAAD, and SCLC are the cancer types where CIC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.102	0.688	<.001	36	view →
PAAD	OS	Median	All	0.112	0.613	<.001	24	view →
SCLC	DFS	Median	II,III,IV	0.082	0.564	.002	24	view →
UCEC	DFS	Median	All	0.919	0.616	.011	20	view →
LGG	DFS	Median	All	0.839	0.346	<.001	16	view →
BLCA	DFS	Median	II,III,IV	0.880	0.605	.022	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
CESC	OS	Median	All	0.574	0.804	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CIC–UCS (OS)

Open the UCS breakdown →